These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 32671305)

  • 21. Incidence of retinopathy in chronic hepatitis C patients treated with pegylated interferon alpha 2a and ribavirin combination therapy.
    Kashif M; Saleem MK; Farooka IK; Husnain A; Siddiqui AM
    Pak J Med Sci; 2015; 31(1):174-7. PubMed ID: 25878638
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of ITPA gene variation and serum ribavirin concentration with a decline in blood cell concentrations during pegylated interferon-alpha plus ribavirin therapy for chronic hepatitis C.
    Nakagawa M; Sakamoto N; Watanabe T; Nishimura-Sakurai Y; Onozuka I; Azuma S; Kakinuma S; Nitta S; Kiyohashi K; Kusano-Kitazume A; Murakawa M; Yoshino K; Itsui Y; Tanaka Y; Mizokami M; Watanabe M;
    Hepatol Int; 2013 Mar; 7(1):153-61. PubMed ID: 26201629
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Several factors including ITPA polymorphism influence ribavirin-induced anemia in chronic hepatitis C.
    Tsubota A; Shimada N; Abe H; Yoshizawa K; Agata R; Yumoto Y; Ika M; Namiki Y; Nagatsuma K; Matsudaira H; Fujise K; Tada N; Aizawa Y
    World J Gastroenterol; 2012 Nov; 18(41):5879-88. PubMed ID: 23139603
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic ductopenic rejection in patients with recurrent hepatitis C virus treated with pegylated interferon alfa-2a and ribavirin.
    Stanca CM; Fiel MI; Kontorinis N; Agarwal K; Emre S; Schiano TD
    Transplantation; 2007 Jul; 84(2):180-6. PubMed ID: 17667809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pegylated interferon alfa and ribavirin for children with chronic hepatitis C.
    Rosen I; Kori M; Eshach Adiv O; Yerushalmi B; Zion N; Shaoul R
    World J Gastroenterol; 2013 Feb; 19(7):1098-103. PubMed ID: 23467199
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Retinopathy associated with pegylated interferon and ribavirin causing permanent visual impairment in a patient with chronic hepatitis C.
    Moisseiev E; Goldenberg D; Kurtz S
    Ophthalmic Surg Lasers Imaging; 2011 Sep; 42 Online():e91-3. PubMed ID: 21899250
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C in patients with congenital coagulation disorders.
    Katsarou O; Theodosiades G; Ioannidou P; Nomikou E; Tsevrenis B; Kouraba A; Deutch M; Terpos E; Dourakis S; Karafoulidou A
    Acta Haematol; 2008; 120(2):63-9. PubMed ID: 18827474
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is combination therapy interferon and ribavirin in patients with chronic hepatitis C infection toxic for eyes?
    Mousa N; Besheer T; Gad Y; Elbendary A; Mokbel T; Abdel-Aziz A
    J Ocul Pharmacol Ther; 2013 Apr; 29(3):345-8. PubMed ID: 23113644
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sofosbuvir, Pegylated Interferon and Ribavirin in the Treatment of an Egyptian Cohort with Hepatitis C Virus Infection in Real-Life Clinical Practice.
    Abd-Elsalam S; Badawi R; Elnawasany S; Yousef M; Mansour L; Hawash N; Elkhouly RA; Soliman S; Selim A; Kobtan A; Elfert A
    Infect Disord Drug Targets; 2019; 19(2):179-184. PubMed ID: 30207250
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Loss of smell (anosmia) and taste (ageusia) in a patient treated with pegylated interferon alfa and ribavirin.
    Mayet AY
    Curr Ther Res Clin Exp; 2007 Jul; 68(4):271-7. PubMed ID: 24683217
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CONSORT: Effects of adding adefovirdipivoxil to peginterferon alfa-2a at different time points on HBeAg-positivepatients: A prospective, randomized study.
    Zhang K; Cao H; Liang J; Shu X; Sun H; Li G; Xu Q
    Medicine (Baltimore); 2016 Aug; 95(31):e4471. PubMed ID: 27495085
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Addition of pentoxifylline to pegylated interferon-alpha-2a and ribavirin improves sustained virological response to chronic hepatitis C virus: a randomized clinical trial.
    Jiménez-Luévano MÁ; Lerma-Díaz JM; Hernández-Flores G; Jiménez-Partida MÁ; Bravo-Cuellar A
    Ann Hepatol; 2013; 12(2):248-55. PubMed ID: 23396736
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders.
    Rustgi VK; Lee WM; Lawitz E; Gordon SC; Afdhal N; Poordad F; Bonkovsky HL; Bengtsson L; Chandorkar G; Harding M; McNair L; Aalyson M; Alam J; Kauffman R; Gharakhanian S; McHutchison JG;
    Hepatology; 2009 Dec; 50(6):1719-26. PubMed ID: 19852040
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results.
    Bacon BR; Shiffman ML; Mendes F; Ghalib R; Hassanein T; Morelli G; Joshi S; Rothstein K; Kwo P; Gitlin N
    Hepatology; 2009 Jun; 49(6):1838-46. PubMed ID: 19291790
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pegylated interferon alpha-2a for treatment of chronic HCV infection in hemodialysis patients: a single Saudi center experience.
    Alsaran K; Sabry A; Shaheen N
    Int Urol Nephrol; 2011 Sep; 43(3):865-73. PubMed ID: 20490669
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of epoetin beta during combination therapy of infection with hepatitis c virus with ribavirin improves a sustained viral response.
    Falasca K; Ucciferri C; Mancino P; Gorgoretti V; Pizzigallo E; Vecchiet J
    J Med Virol; 2010 Jan; 82(1):49-56. PubMed ID: 19950239
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of hematological abnormalities in patients with chronic hepatitis C treated with interferon and ribavirin.
    Nachnani JS; Rao GA; Bulchandani D; Pandya PK; Alba LM
    Ann Hematol; 2010 Feb; 89(2):121-5. PubMed ID: 19565241
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group.
    Glue P; Rouzier-Panis R; Raffanel C; Sabo R; Gupta SK; Salfi M; Jacobs S; Clement RP
    Hepatology; 2000 Sep; 32(3):647-53. PubMed ID: 10960463
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.
    Itokawa N; Atsukawa M; Tsubota A; Kondo C; Hashimoto S; Fukuda T; Matsushita Y; Kidokoro H; Kobayashi T; Narahara Y; Nakatsuka K; Kanazawa H; Iwakiri K; Sakamoto C
    J Gastroenterol Hepatol; 2013 Mar; 28(3):443-9. PubMed ID: 23173698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.